Previous 10 | Next 10 |
In our most recent article, we focused on Iovance ( IOVA ), a cell therapy company that in our opinion has consistently generated positive data, has developed a commercializable product, and is deploying a de-risked clinical strategy for a clear unmet need. As a result, we saw nearly 100% ups...
Adaptimmune Therapeutics ( ADAP ) is a good speculative biotech to look into in considering to add to the portfolio. That's because it announced some preliminary positive data in patients with synovial sarcoma . On the flip side, the data was only achieved in a phase 1 study. There is a c...
Adaptimmune Therapeutics (NASDAQ: ADAP ) announces a 3-year agreement with Cryoport (NASDAQ: CYRX ) to use latter's logistics solutions for its cell therapies. More news on: Adaptimmune Therapeutics plc, Cryoport, Inc., Healthcare stocks news, Read more ...
PHILADELPHIA and OXFORDSHIRE, United Kingdom and IRVINE, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperatur...
Gainers: Akcea Therapeutics (NASDAQ: AKCA ) +29% . Liquid Media Group (NASDAQ: YVR ) +24% . AgeX Therapeutics (NYSEMKT: AGE ) +20% . Sutro Biopharma (NASDAQ: STRO ) +19% . Livongo Health (NASDAQ: LVGO ) +15% . Motus GI Holdings (NASDAQ: MOTS ) +12% . Teekay Tankers (NYSE: TNK )...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announces the appointment of Michael Garone as interim Chief Financial Officer (CFO) effective immediately. ...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented updated data from patients with synovial sarcoma who were treated in the ongoing Phase 1 trial with SP...
Gainers: Francesca's Holdings (NASDAQ: FRAN ) +92% . Mallinckrodt plc (NYSE: MNK ) +64% . Pier 1 Imports (NYSE: PIR ) +41% . YRC Worldwide (NASDAQ: YRCW ) +32% . Endo International (NASDAQ: ENDP ) +29% . Dean Foods Company (NYSE: DF ) +28% . Basic Energy Services (NYSE: BAS ) ...
The FDA has granted Orphan Drug Designation (ODD) to Adaptimmune Therapeutics' (NASDAQ: ADAP ) SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas. More news on: Adaptimmune Therapeutics plc, Healthcare stocks news, Read more ...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SPE...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...